The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: IV. Local treatment failure and enucleation in the first 5 years after brachytherapy. COMS report no. 19

Ophthalmology

Volumn 109, Issue 12, 2002, Pages 2197-2206

  Jampol, Lee M ^a   Moy, Claudia S ^b,c   Murray, Timothy G ^d   Reynolds, Sandra M ^b   Albert, Daniel M ^e   Schachat, Andrew P ^b   Diddie, Kenneth R ^f   Engstrom Jr , Robert E ^g   Finger, Paul T ^h   Hovland, Kenneth R ⁱ   Joffe, Leonard ^j   Olsen, Karl R ^k   Wells, Craig G ^l  

^a NORTHWESTERN UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF WISCONSIN MADISON   (United States)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g JULES STEIN EYE INSTITUTE   (United States)

^h New York Eye Center   (United States)

ⁱ Porter Adventist Hospital   (United States)

^j Retina Associates Southwest PC   (United States)

^k Retina Vitreous Consultants   (United States)

^l UNIVERSITY OF WASHINGTON   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 125;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHOROID MELANOMA; CHOROID TUMOR; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MELANOMA; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; TREATMENT OUTCOME; VISUAL ACUITY;

AGED; BRACHYTHERAPY; CHOROID NEOPLASMS; EYE ENUCLEATION; FEMALE; FUNDUS OCULI; HUMANS; IODINE RADIOISOTOPES; MALE; MELANOMA; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; TREATMENT FAILURE;

EID: 0036895042     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-6420(02)01277-0     Document Type: Article

References (32)

1. Shields JA, Shields CL, Donoso LA. Management of posterior uveal melanoma. Surv Ophthalmol 1991;36:161-95.
2. Finger PT. Radiation therapy for choroidal melanoma. Surv Ophthalmol 1997;42:215-32.
3. Design and methods of a clinical trial for a rare condition: The Collaborative Ocular Melanoma Study. COMS Report No. 3. Collaborative Ocular Melanoma Study Group. Control Clin Trials 1993;14:362-91.
4. Diener-West M, Earle JD, Fine SL, et al. The COMS randomized trial of iodine125 brachytherapy for choroidal melanoma, III. Initial mortality findings. COMS Report No. 18. Collaborative Ocular Melanoma Study Group. Arch Ophthalmol 2001;119:969-82.
5. Garretson BR, Robertson DM, Earle JD. Choroidal melanoma treatment with iodine 125 brachytherapy. Arch Ophthalmol 1987;105:1394-7.
6. Bosworth JL, Packer S, Rotman M, et al. Choroidal melanoma. I-125 plaque therapy. Radiology 1988;169:249-51.
7. Packer S, Stoller S, Lesser ML, et al. Long-term results of iodine 125 irradiation of uveal melanoma. Ophthalmology 1992;99:767-73; discussion 774.
8. Hill JC, Sealy R, Shackleton D, et al. Improved iodine-125 plaque design in the treatment of choroidal malignant melanoma. Br J Ophthalmol 1992;76:91-4.
9. Kreissig I, Rose D, Jost B. Long-term follow-up of iodine-125 brachytherapy for choroidal melanomas. Part I: Anatomical results and life expectancy. Eur J Ophthalmol 1993;3:121-6.
10. Fontanesi J, Meyer D, Xu S, Tai D. Treatment of choroidal melanoma with I-125 plaque. Int J Radiat Oncol Biol Phys 1993;26:619-23.
11. Char DH, Quivey JM, Castro JR, et al. Helium ions versus iodine 125 brachytherapy in the management of uveal melanoma. A prospective, randomized, dynamically balanced trial. Ophthalmology 1993;100:1547-54.
12. 125I) plaque treatment of uveal melanoma. Int J Radiat Oncol Biol Phys 1993;26:613-8.
13. Wilson MW, Hungerford JL. Comparison of episcleral plaque and proton beam radiation therapy for the treatment of choroidal melanoma. Ophthalmology 1999;106:1579-87.
14. 125I brachytherapy versus helium ion irradiation. Ophthalmology 1989;96:1708-15.
15. De Potter P, Shields CL, Shields JA, et al. Plaque radiotherapy for juxtapapillary choroidal melanoma. Visual acuity and survival outcome. Arch Ophthalmol 1996;114:1357-65.
16. Gündüz K, Shields CL, Shields JA, et al. Radiation complications and tumor control after plaque radiotherapy of choroidal melanoma with macular involvement. Am J Ophthalmol 1999;127:579-89.
17. Collaborative Ocular Melanoma Study (COMS) Manual of Procedures. Springfield, VA: National Technical Information Service, 1995. NTIS accession no. PB95-179693.
18. COMS Study Forms Book. Collaborative Ocular Melanoma Study. Springfield, VA: National Technical Information Service, 1998. NTIS accession no. PB98-139629.
19. Echography (ultrasound) procedures for the Collaborative Ocular Melanoma Study. COMS report no. 12, Part I. Collaborative Ocular Melanoma Study Group. J Ophth Nurs Technol 1999;18:143-9.
20. Echography (Ultrasound) Procedures for the Collaborative Ocular Melanoma Study. COMS report no. 12, Part II. Collaborative Ocular Melanoma Study Group. J Ophth Nurs Technol 1999;18:219-32.
21. Accuracy of diagnosis of choroidal melanomas in the Collaborative Ocular Melanoma Study. COMS report no. 1 [published erratum appears in Arch Ophthalmol 1990;108:1708]. Collaborative Ocular Melanoma Study Group. Arch Ophthalmol 1990;108:1268-73.
22. McLean IW, Foster WD, Zimmerman LE, Gamel JW. Modifications of Callender's classification of uveal melanoma at the Armed Forces Institute of Pathology. Am J Ophthalmol 1983;96:502-9.
23. Nath R, Anderson LL, Luxton G, et al. Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. Med Phys 1995;22:209-34.
24. Ray SK, Bhatnagar R, Hartsell WF, Desai GR. Review of eye plaque dosimetry based on AAPM Task Group 43 recommendations. Int J Radiat Oncol Biol Phys 1998;41:701-6.
25. Lee ET. Statistical Methods for Survival Data Analysis, 2nd Ed. New York: John Wiley & Sons, 1992;86-92, 109-12.
26. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
27. Cox DR. Regression models and life-tables. J R Stat Soc B 1972;34:187-220.
28. Zimmerman LE, McLean IW, Foster WD. Does enucleation of the eye containing a malignant melanoma prevent or accelerate the dissemination of tumour cells? Br J Ophthalmol 1978;62:420-5.
29. Eskelin S, Pyrhönen S, Summanen P, et al. Tumor doubling times in metastatic malignant melanoma of the uvea: Tumor progression before and after treatment. Ophthalmology 2000; 107:1443-9.
30. Egan KM, Ryan LM, Gragoudas ES. Survival implications of enucleation after definitive radiotherapy for choroidal melanoma. An example of regression on time-dependent covariates. Arch Ophthalmol 1998;116:366-70.
31. Collaborative Ocular Melanoma Study (COMS) randomized trial of I-125 brachytherapy for medium choroidal melanoma. I. Visual acuity after 3 years. COMS report no. 16. Collaborative Ocular Melanoma Study Group. Ophthalmology 2001;108:348-66.
32. Quality of life assessment in the Collaborative Ocular Melanoma Study. Design and methods. COMS-QOLS report no. 1. COMS Quality of Life Study Group. Ophthalmic Epidemiol 1999;6:5-17.